- Home
- Equipment
- north america
- drug candidate
Show results for
Refine by
Drug Candidate Equipment Supplied In North America
70 equipment items found
by:PSC Biotech® based inNORTH AMERICA
As a leading biotechnology company, MtoZ Biolabs is committed to providing comprehensive, one-stop CRO testing services to scientific research institutions and pharmaceutical companies worldwide. Whether in the early stages of drug discovery, candidate drug evaluation, or preclinical development, MtoZ Biolabs can provide professional technical ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, ...
by:Ainovo Biotech Inc. based inSacramento, CALIFORNIA (USA)
AlOptimus™ brings to bear AINovo's proprietary machine learning algorithms on our highly curated datasets to enhance the therapeutic profiles of drug candidates. The AlOptimus platform optimizes validated candidates to derisk development and inform clinical ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and Amgen are developing CX-904, a T-cell engaging bispecific Probody candidate against Epidermal Growth Factor Receptor (EGFR) and CD3. The drug candidate is advancing towards IND-enabling studies. CytomX is responsible for the IND filing, targeted for late 2021, and for early clinical development with Amgen leading later stage ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these patentable molecules is further screened to see how changes to its makeup alter its effects and whether the new molecule might be used ...
Manufactured by:Jericho Sciences, LLC based inDurham (RTP), NORTH CAROLINA (USA)
Jericho is developing a new therapeutic drug for FIV infection in cats, working toward a New Animal Drug Application (NADA) with the FDA. Our ongoing studies indicate that Jericho’s small molecule drug candidate can reduce FIV virus levels in chronically-infected cats for many months in the absence of continuing treatment. ...
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
DearDTI presents drug candidates with a good efficacy by predicting the binding affinity, based on information about the compound-protein ...
Manufactured by:Symberix, Inc. based inDurham, NORTH CAROLINA (USA)
Symberix is advancing a portfolio of first-in-class drug candidates for multiple adjunct and monotherapeutic indications. Our discovery platform enables precise targeting of bacteria implicated in intestinal toxicity and gastrointestinal disease. By identifying specific bacterial enzyme targets, we can develop small molecule drugs to block ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Evaluate drug candidate toxicity at clinically relevant concentrations in a co-culture human kidney model. Predicting drug-induced kidney toxicity and drug-drug interactions continues to be a challenge due to a reliance on immortalized cell line culture or animal models that do not translate to human response. ...
Manufactured by:Enalare Therapeutics Inc. based inPrinceton, NEW JERSEY (USA)
Our lead drug candidate, ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials during the fourth quarter of 2021. With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential of dramatically improving the lives of those impacted by several life threatening conditions including ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Study lung physiology, disease, and the effect of drug candidates. A more human-relevant model for studying pulmonary physiology, with primary human cells in a lung-specific microenvironment. We are currently developing two distinct models of the human lung—the Alveolus Lung-Chip and the Airway Lung-Chip—to capture the specific tissue architecture and ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of delivery of AOB with treatment durations ranging from two to 12 weeks. Regardless of dose, mode of delivery, indication targeted, or age of patients, our bacterial drug ...
by:Curemark based inRye Brook, NEW YORK (USA)
Centers for Disease Control and Prevention estimate that 1 in 68 children in the United States have been diagnosed with Autism. There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that. Curemark’s lead drug candidate, CM-AT, has received “Fast Track” ...
Manufactured by:SEngine Precision Medicine based inSeattle, WASHINGTON (USA)
Guiding drug discovery with proprietary high throughput 3D patient cell technology and genomics will drastically increase the success of novel drug candidates and directly result in faster development at reduced costs. SEngine Precision Medicine’s innovative approach brings diagnostics, drug discovery and proprietary ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Investigate mechanisms of colon inflammation and barrier disruption and evaluate the efficacy of anti-inflammatory drug candidates in an organoid-derived ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. A key component of this drug candidate, the QN-165 aptamer, has ...